Commercial agreement
September 13 2010 - 2:00AM
UK Regulatory
TIDMONG
RNS Number : 5389S
Oxford Nutrascience Group PLC
13 September 2010
Oxford Nutrascience Group plc
("Oxford Nutrascience" or "the Company")
Commercial agreement with leading provider of outsourced services to the health
and beauty markets
Oxford Nutrascience has signed a non-exclusive commercial agreement for its
Chewitab(TM) technology with DCC Health & Beauty Solutions Ltd., the leading
provider of outsourced services to the health and beauty markets. Oxford
Nutrascience will earn royalties on all Chewitab enabled products sold by DCC
Health & Beauty Solutions in the UK and Ireland.
Under the terms of the open-ended agreement DCC Health & Beauty Solutions will
license Oxford Nutrascience's technology for the manufacture and sale of
chewable tablets. DCC Health & Beauty Solutions will have the ability to use
Chewitab for an unlimited range of applications, including the production of
healthcare supplements.
DCC Health & Beauty Solutions provides services to leading premium brand owners,
mail order companies and global health and beauty retailers. Their customer base
includes; Merck, GSK, Healthspan and Vitabiotics.
Chewitab is Oxford Nutrascience's proprietary technology used in chewable
tablets. Chewitabs produce a light crunch when bitten and dissolve quickly in
the mouth resulting in a soft pleasant mouth feel with no grittiness and can be
taken without water.
This key differentiator makes Chewitabs a highly convenient delivery system and
particularly well suited for Over The Counter medicines (such as analgesics,
allergy treatments, digestive aids) and medicines for the elderly as well as
vitamins and supplements.
DCC Health & Beauty Solutions is part of DCC plc, a business support services
group listed on the Irish and London Stock Exchanges with revenues of EUR6.7
billion. DCC Health & Beauty Solutions is a high growth business, driven by its
proactive approach to new product development, its ability to react quickly to
market dynamics and the quality of its MHRA licenced facilities. It provides
services to the companies behind many of the most successful supplement brands
on the shelves in the UK today.
Nigel Theobald, Chief Executive, Oxford Nutrascience Group Plc commented:
"Securing a licensing agreement for Chewitab with the UK's largest healthcare
contract supplier so soon since the IPO of the Company demonstrates the strength
of our business model and validates the efficacy of our technology.
"The interest being shown by a number of global healthcare companies in our
chewable and soluble products is being fueled by healthcare organisations
striving to find ways to extend their product life cycles. This is creating
growing demand for more innovative delivery systems and superior product
performance and Chewitab provides a solution to this challenge.
"DCC Health & Beauty Solutions have an outstanding track record of exploiting
markets with high performing products and we look forward to exploring other
products ideas with them."
Rachell Hipkiss, Development Director, DCC Health & Beauty Solutions, commented:
"DCC Health & Beauty Solutions specialises in the provision of outsourced
product development, manufacturing, packing and other services to the health and
beauty industry in Europe.
"Oxford Nutrascience, with its innovative ideas, fits perfectly with the
objective of DCC Health & Beauty Solutions of bringing exciting new solutions to
market. We are excited about the prospects for Chewitab and look forward to
working with our customers to launch of our Chewitab based products."
For further information:
Oxford Nutrascience Group Plc
Nigel Theobald, Chief Executive +44 1865
854874
Mark Way, Investor and Media Relations +44 7786 116991
DCC Health & Beauty Solutions Ltd +44 1928 573734
Rachell Hipkiss, Development Director
ZAI Corporate Finance (Nominated Adviser)
Ray Zimmerman +44 20
7060 2220
Sarang Shah +44
20 7060 2220
About Oxford Nutrascience Group Plc
www.oxfordnutrascience.com
· Oxford Nutrascience is a UK consumer healthcare company that develops
chewy confectionery, chewable tablets and liquid suspensions to allow medicines
and vitamin supplements to be taken in a more pleasant and convenient way.
· Oxford Nutrascience has developed technology for the use of soluble
fibres in medicine delivery systems that disperse and solubilise medicines,
improve taste and mouth feel, simplify processing and eliminate additives,
incorporate prebiotic health benefits.
· Chews: Oxford Nutrascience currently produces Ellactiva , a calcium chewy
supplement sold in the UK and in the Middle East, and plans to launch new chews
to complement this existing product.
· Chewable tablets and liquid suspensions: The target market for Oxford
Nutrasciences' Chewitabs(TM) and liquid suspension delivery systems are
over-the-counter ("OTC") pain relieving drugs, indigestion preparations and
cough and cold medicines.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGREAANAFESEEAF
Oxford Nutrascience (LSE:ONG)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oxford Nutrascience (LSE:ONG)
Historical Stock Chart
From Dec 2023 to Dec 2024